Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746959 | 1.00 | KDM4E (0.57) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL14248268 | 0.94 | KDM4E (0.52) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL11883542 | 0.82 | CYP1A2 (0.52) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL17919704 | 0.79 | CYP2A6 (0.52) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL3372681 | 0.79 | CYP1A2 (0.50) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL12632888 | 0.79 | NPC1 (0.58) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL12250941 | 0.79 | GABRP (0.54) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL6971528 | 0.78 | CYP1A2 (0.48) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL21965360 | 0.78 | GABRP (0.51) | KDM4ENPC1RAB9ACYP1A2CYP2A6 | |
| SCHEMBL587832 | 0.78 | MAPT (0.42) | KDM4ENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903192-A | Preparation method of 3-methoxy isoquinoline compound intermediate | 上海相辉医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | SHANGHAI EAST HOSPITAL (CN) | 2025-01-07 | — | — | US | disclosed |
| WO-2024088069-A1 | PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-117903192-A | Preparation method of 3-methoxy isoquinoline compound intermediate | 上海相辉医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903192-A | Preparation method of 3-methoxy isoquinoline compound intermediate | 上海相辉医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903192-A | Preparation method of 3-methoxy isoquinoline compound intermediate | 上海相辉医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114401935-B | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2024-04-05 | — | — | CN | disclosed |
| CN-117327053-A | Preparation method of PKC inhibitor darovasertib | 云南万宏医药科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117263959-A | Preparation and application of aromatic KRAS mutant protein inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6599908-B1 | Potent and selective inhibitors of the protein tyrosine kinases p56lck and p59fyn | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| US-6057329-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0946523-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028281-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-4075344-A | 3-ALKOXYISOQUINOLINES FOR HYPOTENSIVE AND VASODILATING EFFECTS | MEAD JOHNSON & COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4015006-A | 3(2H)-Isoquinolones therapeutic process | MEAD JOHNSON & COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | KDM4E 3795/4885NPC1 355/4885RAB9A 3351/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | KDM4E 2792/4885NPC1 378/4885RAB9A 617/4885 |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | CACNA1F, CACNA1S, CACNA1D | KDM4E 3795/4885NPC1 355/4885RAB9A 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.